[{"countryName":"Worldwide","languageLinks":[{"languageName":"English","languageUrl":"/en.html"}]},{"countryName":"USA","languageLinks":[{"languageName":"English","languageUrl":"/en-us.html"}]},{"countryName":"Japan","languageLinks":[{"languageName":"Japanese","languageUrl":"/jp/ja.html"}]}]
The link you have selected will take you outside of the Roche Sequencing USA website.
AVENIO ctDNA Analysis Kits
Overview
AVENIO ctDNA Analysis Kits are a portfolio of three NGS liquid biopsy assays for oncology research. Using a streamlined workflow to evaluate ctDNA extracted from plasma, these assays provide an end-to-end solution for tumor profiling, longitudinal monitoring of tumor burden, and minimal residual disease (MRD) detection.
Key Advantages of AVENIO ctDNA Analysis Kits
- Matched ctDNA and tissue panels (same genes, gene regions and hybrid-capture workflow) to facilitate concordance analysis
- Includes genes in the U.S. National Comprehensive Cancer Network (NCCN) Guidelines1
- All four mutation classes (SNVs, indels, fusions and CNVs) in a single assay
- Exceptional analytical performance supported by integrated digital error suppression (iDES) strategies combining molecular barcodes with in silico error suppression techniques2,3
- Includes reagents for DNA extraction, library preparation and target enrichment, as well as bioinformatics and software required to analyze sequencing data and generate reports
- Streamlined, end-to-end workflow from extraction to analysis and reporting in five days
AVENIO ctDNA
Targeted Kit
A 17-gene (81kb) pan-cancer assay containing genes in NCCN guidelines and optimized for lung cancer and colorectal cancer research.
AVENIO ctDNA
Expanded Kit
A 77-gene (192kb) pan-cancer assay containing genes in the NCCN guidelines and emerging biomarkers, and optimized for lung cancer and colorectal cancer applications.
AVENIO ctDNA
Surveillance Kit
A 197-gene (198kb) assay, containing 17 NCCN guideline-aligned genes, plus 471 frequently mutated disease-associated regions across 197-genes; optimized for longitudinal monitoring of tumor burden in lung and colorectal cancer.
- National Comprehensive Cancer Network. October 15, 2016.
- Newman AM, Lovejoy AF, Klass DM, et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nature Biotechnology. 2016;34(5):547–555. doi:10.1038/nbt.3520.
- Data on file.